{"name":"Orchard Therapeutics","slug":"orchard","ticker":"ORTX","exchange":"NASDAQ","domain":"orchard-tx.com","description":"Orchard Therapeutics is a gene therapy company focused on rare neurometabolic disorders. The company has a pipeline of gene therapies targeting various indications, including ADA-SCID and MLD. Orchard Therapeutics has a strong market position in the gene therapy space, with several products in development. The company is headquartered in London and has a presence in the US.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Bobby Gaspar","sector":"Gene Therapy / Rare Neurometabolic","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$680M","metrics":{"revenue":85000000,"revenueGrowth":1252.5,"grossMargin":0,"rdSpend":93847000,"netIncome":-150660000,"cash":218907000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"OTL-200 patent cliff ($0.0B at risk)","drug":"OTL-200","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"OTL-203 patent cliff ($0.0B at risk)","drug":"OTL-203","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Orchard Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Orchard Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $44.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Orchard Therapeutics Announces Collaboration with the National Institute of Neurological Disorders and Stroke (NINDS)","summary":"Orchard Therapeutics announced a collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) to develop gene therapies for rare neurometabolic disorders.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Orphan Drug Designation to OTL-200 for the Treatment of MLD","summary":"The FDA granted orphan drug designation to OTL-200 for the treatment of metachromatic leukodystrophy (MLD).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNc0d5Tk1ra3RHNmxfSktfOHhPcGh6ZTFXbmRleWdzci15WmhhYWRHQV9qN2dja25sT3RiczRkSnFYazE3bEJZQ1JiZ3VuM19RSE9yUVpieGhQUmZaMGpoMHBoTC1hdVVCMUZDbFRVRDMxUGg2ZHBjRmJpakxZLU40U254WHBVWW9SWmZvNzNUcEJvUzlLSTlBMjRqRnZmRklLclBvdm5R?oc=5","date":"2025-08-04","type":"pipeline","source":"Equities.com","summary":"Michael McTague: How can anyone afford breakthrough medicines? - Equities.com","headline":"Michael McTague: How can anyone afford breakthrough medicines?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPaVVxUUJHMF9kaTRQWmNEbUxZWWZpY252b0dia3RtRU94OHdQZERrZWw3OVNhWUpKNmpmdlZSQS1jaTBJbU9LR29rN0doNVdZU3ZXNFpjenpwdUlveFdWZnQ0NUFkbW9WeldxWjhWZ05LT1B1Z1ZURzVETUJiY1RsYkxNclVweklnQVlpaFphcmo?oc=5","date":"2024-12-20","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 cell and gene therapy leaders to watch in 2025 - drugdiscoverytrends.com","headline":"100 cell and gene therapy leaders to watch in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNV3dEZHJlaGpQMnBOTmFTelRnSTFEdi1EMnVVS1Z2a0ZqWHVRYW9VNmxyd2owVlFneVdWT1czMkpTNkxqRHpMUEhUbzhadGZWWVNQclJkeUNPUEFRS283YzVrUERUN0lwLWppbEZNaFU3QWlmVjRUeDVVLUNjUXFkblhZZHJER2Npa1J4bFhn?oc=5","date":"2024-03-20","type":"regulatory","source":"The Business Journals","summary":"Orchard’s newly approved gene therapy is most expensive drug in history - The Business Journals","headline":"Orchard’s newly approved gene therapy is most expensive drug in history","sentiment":"positive"},{"date":"2024-02-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPeWpHV18wY3JOZUFVS28tZm54WVE1ZHJQaDdpbmFRaHBaWnZmcllNR1VWZXZCaHBxSEJfeEJTcTM5eFNhZFB3amdNanBPS1VVSnVqcDlFZ1kxeFV4WTlJdkk0WHJDYTBQdkZkNVZkTzNoc1ZyZUpBYTZPNXhYcHQwN2NvRU1ialB0ZDlyWkFMakhBUldvanotY29nRGFxUQ?oc=5","date":"2023-10-09","type":"deal","source":"University College London","summary":"UCL spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m | UCL News - UCL - University College London","headline":"UCL spinout Orchard Therapeutics to be acquired by Kyowa Kirin for $477m | UCL News - UCL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPY1c2U1VMRjUyUF9ud1RveTV0Zl9YaHVkWVpLRnRNZ0JoRnB1UHZtaFlhc2MwT3NDbURrd0RkWHprcmtvdVFZZEo2eG94WUEtRVJQdTlldXByZ19OZ1dCUnhVeTZ3TjFRQXZQTzVmdkpHSkVvUXFZdFBINlh6dDFLSHJWazk?oc=5","date":"2023-10-06","type":"deal","source":"Yahoo Finance","summary":"Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin - Yahoo Finance","headline":"Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNZ29WMG1oVVRBcFh4YWllLXBVN3ZxaUUwLWdweVdpcjF2bFB3R19lUlVqaDA4OWpTRGdOcVpGenFEVHI0bHE5eENGMzRnSlh4dWs0WFc1OHpOczk5OXZRX2lMZDVUYXlIYWZuMl9OdGlWUVN4R0NTWkdNS2kyT2VSWW9LN0NSZzlBTnpBUHJ6UU1Jdw?oc=5","date":"2023-10-05","type":"pipeline","source":"Invezz","summary":"Orchard Therapeutics is being bought at a massive premium - Invezz","headline":"Orchard Therapeutics is being bought at a massive premium","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE43a3dLQTNkNVRuYnYyNUt5Q0RWNmZNZEIyelBGWFBfX1o5RFg3YjlpOFEtcGdfY2ZyLXVLeGRXZER2WldIdnFid2UyUFA5YVpfNHJzV0txdXVlQUdUZWthUkZaTFU5Wkh5eEhpbElEZVZHQXUxMVUtYQ?oc=5","date":"2021-03-08","type":"pipeline","source":"Market Realist","summary":"Wall Street Is Bullish on ORTX Stock, Outlook in 2021 - Market Realist","headline":"Wall Street Is Bullish on ORTX Stock, Outlook in 2021","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxNTHdrVHdnS1BjWVhrRUd1QTh1aExMWGdRRi1Dc2cyZjQ2a2lvd1IxNHJsd0p2TlRQejRqVWJPTzdPV2NMaENYaGtiVVVpcjN0TU8yMFFiZkN4UE9Rc1hyYzRwRUZoTVc4T3lzTW5QeDJVSDZWTHEwZkJuS1ZpaW16ak9TVjh5R1B5Q2VaU183NGIzd01YcVJhbmFaZ3ZNZkJKc0ZldlNOX0lVYzg5S1FpZUNzMzFqOUhsc1A4UjNEY1VvTUlBU0ctd1JEWFVOd2V3dTFvM1k0U25kbC05QmVMNE9zOElEOWlVdkpNLWNfOUF5c3FaWEZQSnA2Q0NOa2p2S1BSUXdZNkhUc3J2anpHMWlvRUNuMkVaVjFmSA?oc=5","date":"2020-12-21","type":"regulatory","source":"globenewswire.com","summary":"Orchard Therapeutics Receives EC Approval for Libmeldy™ for - globenewswire.com","headline":"Orchard Therapeutics Receives EC Approval for Libmeldy™ for","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPWFlDV1BMWTRxdkRyZVJpVDg1bDA2RGwzTVo5NHpCdS1rekF4Zzl1Q0lka2RqTkd4VEp0amdBV1hIdFhnMzNvek0tOS1iMzdkT1pHbXQ5MDRGUXcweUE1WnZBd1hSclhmMHc1WVFCQnl0b3JvV3llWjJ5SzZheU80Uy1keVRkNWVCUlVMXzgwV1c0MW94TUROZGFpZE14cUdQY0c0Z0pn?oc=5","date":"2018-12-13","type":"pipeline","source":"The Business Journals","summary":"Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay - The Business Journals","headline":"Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1kSjMzUktJNnFkZEEtd0FJbG5XMHA5YU1mNFJFdkR3UEtxamM3dTZBbG4ydWpjWU5iR0dxWHJydi1NTUI4amZxNjU4aU1lNFJBSDFIazlnRU9jTUNUcXBwNzJVTlRlbzhoQUJKQ2h3?oc=5","date":"2018-05-15","type":"pipeline","source":"Labiotech.eu","summary":"Here Are 10 of the Hottest Biotech Hubs in Europe - Labiotech.eu","headline":"Here Are 10 of the Hottest Biotech Hubs in Europe","sentiment":"neutral"}],"patents":[{"drugName":"OTL-200","drugSlug":"metachromatic-leukodystrophy","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"OTL-203","drugSlug":"ada-scid","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sangamo Therapeutics","Voyager Therapeutics","uniQure"],"therapeuticFocus":["Rare Neurometabolic Disorders","Gene Therapy"],"financials":{"source":"sec_edgar+yahoo","revenue":22655000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":22655000,"period":"2022-12-31"},{"value":1675000,"period":"2021-12-31"},{"value":1675000,"period":"2021-12-31"},{"value":2595000,"period":"2020-12-31"},{"value":2595000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":93847000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-150660000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":218907000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}